Nanjing NingQi Medicine Science and Technology Co., Ltd. Report issue

Government Phase 2 Phase 3 Phase 4
Founded: Nanjing China

Organization Overview

First Clinical Trial
2014
NCT02520219
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Nanjing NingQi Medicine Science and Technology Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 4)

Carcinoma, Squamous Cell (Phase 4)

Colonic Neoplasms (Phase 3)

Lung Neoplasms (Phase 4)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 16